Profound Medical CFO Rashed Dewan Resigns; Matthew Sobczyk Named Interim CFO
PROF sits 76% above its 52-week low of $3.76.
Summary
Profound Medical announced the resignation of CFO Rashed Dewan and the appointment of Matthew Sobczyk as Interim CFO, effective August 14, 2026. The transition includes a $375,000 severance payment and a consulting agreement through November 2026.
Key Events · Executive and Board Changes · PROF
-
CFO Resignation
Rashed Dewan resigned as CFO effective August 14, 2026, after serving in the role. The company entered into a Mutual Separation Agreement providing a $375,000 cash severance payment.
-
Interim CFO Appointment
Matthew Sobczyk, previously Corporate Controller, was appointed Interim CFO effective August 14, 2026. He receives an annual base salary of CAD 300,414.58 and a target bonus of 15% of base salary.
-
Transition Services Agreement
Dewan will provide consulting services from August 17 to November 25, 2026, at CAD 200 per hour, and will continue vesting of 20,000 restricted share units.
-
Severance and Benefits
The company will pay employer contributions to maintain Dewan's employee benefits for 15 months and reimburse up to CAD 5,000 in legal fees.
Analysis · PROF · Industrial Applications And Services
A CFO transition at Profound Medical took effect on August 14, 2026, with Rashed Dewan stepping down and Corporate Controller Matthew Sobczyk promoted to Interim CFO. The handover includes a $375,000 severance payment and a short-term consulting agreement to ensure continuity. While the company has a strong internal successor, the abrupt CFO change introduces uncertainty during a period of revenue growth and ongoing commercialization of its TULSA-PRO technology.
At the time of this filing, PROF was trading at $6.60 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $242.2M. The 52-week trading range was $3.76 to $8.95. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.